• Earlier in May 2026, Viking Therapeutics presented additional Phase 2 data on its oral VK2735 obesity candidate at the European Congress on Obesity in Istanbul, highlighting statistically significant, dose-dependent weight loss of up to 12.2% over 13 weeks with mostly mild to moderate gastrointestinal side effects.
• The new poster emphasized that higher oral VK2735 doses drove early, progressive weight loss without a plateau through Week 13, while a titration approach appeared to help manage gastrointestinal tolerability, reinforcing the therapy’s potential fit for real-world obesity patients with cardiometabolic risk factors.
• We’ll now examine how this Phase 2 oral VK2735 weight-loss profile, including early efficacy without plateau, influences Viking Therapeutics’ investment narrative.

Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

Viking Therapeutics Investment Narrative Recap

To own Viking Therapeutics, you need to believe VK2735 can convert strong mid stage obesity data into successful Phase 3 outcomes and eventual commercialization despite ongoing losses and cash burn. The ECO 2026 oral VK2735 update supports the short term catalyst around upcoming VANQUISH Phase 3 readouts, but does not eliminate the key risk that late stage trials or future regulatory reviews could still introduce safety, efficacy or timing setbacks.

The ECO 2026 presentation directly builds on Viking’s earlier update that VANQUISH 2, the subcutaneous VK2735 Phase 3 trial in adults with obesity and type 2 diabetes, has completed enrollment. Together, these announcements keep attention on a clustered set of catalysts around Phase 3 data across injectable and future oral programs, while the company continues to report sizeable net losses as it funds these large, late stage studies.

Yet investors also need to be aware that, despite the encouraging oral VK2735 data, Viking’s rising R&D spend and reliance on its cash balance could...

Viking Therapeutics' narrative projects $118.5 million revenue and $12.9 million earnings by 2029. This requires revenue to grow from zero and an earnings increase of about $372.5 million from -$359.6 million today.

Uncover how Viking Therapeutics' forecasts yield a $92.72 fair value, a 200% upside to its current price.

Exploring Other Perspectives

Some analysts were already projecting Viking could reach about US$497.5 million in revenue and US$62.2 million in earnings by 2029, a far more optimistic path than consensus, and the new VK2735 results may prompt you to reconsider how realistic that upside is compared with the execution and funding risks still in front of the company.

Explore 15 other fair value estimates on Viking Therapeutics - why the stock might be worth less than half the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Viking Therapeutics research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Viking Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viking Therapeutics' overall financial health at a glance.

Searching For A Fresh Perspective?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality.
• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.